Current and Emerging Immunotherapies for Castration-resistant Prostate Cancer

Urology

Volumn 85, Issue 5, 2015, Pages 976-986

  Saad, Fred ^a   Miller, Kurt ^b  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DENOSUMAB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IMMUNE CHECKPOINT INHIBITOR; IMMUNOMODULATING AGENT; IPILIMUMAB; RILIMOGENE GALVACIREPVEC; SIPULEUCEL T; TASQUINIMOD; UNCLASSIFIED DRUG; ZOLEDRONIC ACID; MONOCLONAL ANTIBODY; VACCINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; DRUG EFFICACY; DRUG SCREENING; HUMAN; MALE; METASTATIC MELANOMA; MULTICENTER STUDY (TOPIC); OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; IMMUNOTHERAPY; PROCEDURES; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOTHERAPY; MALE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VACCINES;

EID: 84933505752     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2014.12.029     Document Type: Review

References (46)

1. J. Ferlay, I. Soerjomataram, M. Ervik, and et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet] 2013 International Agency for Research on Cancer Lyon, France Available at http://globocan.iarc.fr/Pages/fact-sheets-cancer.aspx Accessed August 28, 2014
2. National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer V2 2014 Available at http://www.nccn.org/professionals/physician-gls/pdf/prostate.pdf Accessed August 28, 2014
3. D.R. Berthold, G.R. Pond, F. Soban, and et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study J Clin Oncol 26 2008 242 245
4. D.P. Petrylak, C.M. Tangen, M.H. Hussain, and et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 2004 1513 1520
5. I.F. Tannock, R. de Wit, W.R. Berry TAX 327 Investigators Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512
6. J.S. de Bono, S. Oudard, M. Ozguroglu TROPIC Investigators Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 2010 1147 1154
7. J.S. de Bono, C.J. Logothetis, A. Molina COU-AA 301 Investigators Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 2011 1995 2005
8. H.I. Scher, K. Fizazi, F. Saad AFFIRM Investigators Increased survival with enzalutamide in prostate cancer after chemotherapy N Engl J Med 367 2012 1187 1197
9. C. Parker, S. Nilsson, D. Heinrich ALSYMPCA Investigators Alpha emitter radium-223 and survival in metastatic prostate cancer N Engl J Med 369 2013 213 223
10. C.J. Ryan, M.R. Smith, J.S. de Bono COU-AA-302 Investigators Abiraterone in metastatic prostate cancer without previous chemotherapy N Engl J Med 368 2013 138 148
11. T.M. Beer, A.J. Armstrong, D.E. Rathkopf the PREVAIL Investigators Enzalutamide in metastatic prostate cancer before chemotherapy N Engl J Med 371 2014 424 433
12. P.O. Gannon, A.O. Poisson, N. Delvoye, and et al. Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients J Immunol Methods 348 2009 9 17
13. K.F. May Jr., J.L. Gulley, C.G. Drake, and et al. Prostate cancer immunotherapy Clin Cancer Res 17 2011 5233 5238
14. E. Cha, and E.J. Small Is there a role for immune checkpoint blockade with ipilimumab in prostate cancer? Cancer Med 2 2013 243 252
15. W.R. Gerritsen, and P. Sharma Current and emerging treatment options for castration-resistant prostate cancer: a focus on immunotherapy J Clin Immunol 32 2012 25 35
16. H.Y. Kong, and J. Byun Emerging roles of human prostatic acid phosphatase Biomol Ther (Seoul) 21 2013 10 20
17. P.W. Kantoff, C.S. Higano, N.D. Shore IMPACT Study Investigators Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 411 422
18. P.F. Schellhammer, G. Chodak, J.B. Whitmore, and et al. Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial Urology 81 2013 1297 1302
19. C.S. Higano, J.M. Corman, D.C. Smith, and et al. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer Cancer 113 2008 975 984
20. Higano C, Saad F, Somer B, et al. A phase III trial of GVAX immunotherapy for prostate cancer vs. docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC) [abstract LBA150]. Proc Am Soc Clin Oncol. Genitourinary Cancer Symposium, 2009.
21. Small E, Demkow T, Gerritsen W et al. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel vs. docetaxel plus prednisone in symptomatic, castration resistant prostate cancer (CRPC) [abstract 7]. Proc Am Soc Clin Oncol. Genitourinary Cancer Symposium, 2009.
22. A.J. van den Eertwegh, J. Versluis, H.P. van den Berg, and et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose escalation trial Lancet Oncol 13 2012 509 517
23. R.A. Madan, P.M. Arlen, M. Mohebtash, and et al. Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer Expert Opin Investig Drugs 18 2009 1001 1011
24. P.W. Kantoff, T.J. Schuetz, B.A. Blumenstein, and et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer J Clin Oncol 28 2010 1099 1105
25. R.A. Madan, J.L. Gulley, W.L. Dahut, and et al. Overall survival (OS) analysis of a phase II study using a pox viral-based vaccine, PSA-TRICOM, in the treatment of metastatic, castration-resistant prostate cancer (mCRPC): implications for clinical trial design J Clin Oncol 26 15 suppl 2008 Abstract 3005
26. R. Pili, M. Häggman, W.M. Stadler, and et al. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer J Clin Oncol 29 2011 4022 4028
27. E. Raymond, A. Dalgleish, J.E. Damber, and et al. Mechanisms of action of tasquinimod on the tumour microenvironment Cancer Chemother Pharmacol 73 2014 1 8
28. A.J. Armstrong, M. Häggman, W.M. Stadler, and et al. Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer Clin Cancer Res 19 2013 6891 6901
29. D. Pardoll, and C. Drake Immunotherapy earns its spot in the ranks of cancer therapy J Exp Med 209 2012 201 209
30. C. Robert, L. Thomas, I. Bondarenko, and et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma N Engl J Med 364 2011 2517 2526
31. F.S. Hodi, S.J. O'Day, D.F. McDermott, and et al. Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
32. D. Schadendorf, F.S. Hodi, C. Robert, and et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma [e-pub ahead of print] J Clin Oncol 2015 PII: JCO.2014.56.2736
33. J.D. Wolchok, A. Hoos, S. O'Day, and et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria Clin Cancer Res 15 2009 7412 7420
34. E.J. Small, N.S. Tchekmedyian, B.I. Rini, and et al. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer Clin Cancer Res 13 2007 1810 1815
35. S.F. Slovin, C.S. Higano, O. Hamid, and et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study Ann Oncol 24 2013 1813 1821
36. S. Demaria, N. Kawashima, A.M. Yang, and et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer Clin Cancer Res 11 2005 728 734
37. E.D. Kwon, C.G. Drake, H.I. Scher CA184-043 Investigators Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial Lancet Oncol 15 2014 700 712
38. C.J. Pezaro, A. Omlin, D. Lorente, and et al. Visceral disease in castration-resistant prostate cancer Eur Urol 65 2014 270 273
39. C. Parker A near miss for prostate cancer immunotherapy Lancet Oncol 15 2014 669 671
40. Beer TM, Logothetis C, Sharma P, et al. CA184-095: A Randomized, Double-Blind, Phase 3 Trial to Compare the Efficacy of Ipilimumab vs Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naïve Castration-Resistant Prostate Cancer. Presented At: Annual Meeting of the American Society of Clinical Oncology; May 31-June 4, 2013; Chicago, IL. Poster TPS5093.
41. C.G. Drake, P. Sharma, and W. Gerritsen Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy Oncogene 33 2014 5053 5064
42. Tollefson MK, Karnes RJ, Thompson RH. A Randomized Phase II Study of Ipilimumab With Androgen Ablation Compared With Androgen Ablation Alone in Patients With Advanced Prostate Cancer. Presented At: 2010 Genitourinary Cancers Symposium; March 5-7, 2010; San Francisco, CA. Abstract 168.
43. Y. Loriot, C. Massard, and K. Fizazi Recent developments in treatments targeting castration-resistant prostate cancer bone metastases Ann Oncol 23 2012 1085 1094
44. F. Saad, D.M. Gleason, R. Murray Zoledronic Acid Prostate Cancer Study Group A randomized, placebo controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma J Natl Cancer Inst 94 2002 1458 1468
45. F. Saad, D.M. Gleason, R. Murray Zoledronic Acid Prostate Cancer Study Group Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone refractory prostate cancer J Natl Cancer Inst 96 2004 879 882
46. K. Fizazi, M. Carducci, M. Smith, and et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study Lancet 377 2011 813 822